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I nt h er e c e n ty e a r s ,t h ep e r o x i s o m ep r o l i f e r a t o r - a c t i v a t e dr e c e p t o r - γ (PPAR-γ), a well known target for type II diabetes treatment,
has received an increasing attention for its therapeutic potential in inﬂammatory and degenerative brain disorders. PPAR-γ
agonists, which include naturally occurring compounds (such as long chain fatty acids and the cyclopentenone prostaglandin
15-deoxy Δ
12,14 prostaglandin J2), and synthetic agonists (among which the thiazolidinediones and few nonsteroidal anti-
inﬂammatory drugs) have shown anti-inﬂammatory and protective eﬀects in several experimental models of Alzheimer’s and
Parkinson’s diseases, amyotrophic lateral sclerosis, multiple sclerosis and stroke, as well as in few clinical studies. The pleiotropic
eﬀects of PPAR-γ agonists are likely to be mediated by several mechanisms involving anti-inﬂammatory activities on peripheral
immune cells (macrophages and lymphocytes), as well as direct eﬀects on neural cells including cerebral vascular endothelial
cells, neurons, and glia. In the present article, we will review the recent ﬁndings supporting a major role for PPAR-γ agonists
in controlling neuroinﬂammation and neurodegeneration through their activities on glial cells, with a particular emphasis on
microglial cells as major macrophage population of the brain parenchyma and main actors in brain inﬂammation.
Copyright © 2008 A. Bernardo and L. Minghetti. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
The peroxisome proliferator-activated receptor-γ (PPAR-γ)
belongs to the hormone nuclear receptor super family. It is
a ligand-dependent transcription factor activated by both
naturally occurring compounds, such as long chain fatty
acids and the cyclopentenone prostaglandin 15-deoxy Δ12,14
prostaglandin J2 (15d-PGJ2), and synthetic agonists, includ-
ing the thiazolidinediones (TZDs), and few nonsteroidal
anti-inﬂammatory drugs (NSAIDs). Because of their role in
the regulation of genes involved in lipid and carbohydrate
metabolism,PPAR-γ andtheothertwoisoformsPPAR-αand
δ,d e e p l ya ﬀect lipid homeostasis and insulin sensitivity [1–
3]. The TZDs rosiglitazone (Avandia), and pioglitazone
(Actos), introduced on the market in the early 1990s, are
currently in clinical use to control blood glucose levels in
subjects aﬀected by type II diabetes.
In the last decade, accumulating evidence suggests
that, besides diabetes and metabolic syndrome [4], PPAR-
γ agonists have signiﬁcant therapeutic potential in brain
disorders. A large number of experimental studies and few
clinicalobservationshavesuggestedthatPPAR-γ ligandsmay
be successfully exploited to treat a wide range of neurological
diseases, ranging from neurodegenerative diseases, to trau-
matic injuries, stroke, and demyelinating diseases, as recently
reviewed by Heneka et al. [5]. In Alzheimer’s disease (AD)
transgenic mouse models, the TZD rosiglitazone attenuated
learning and memory deﬁcits [6], in line with its ability to
promote cognitive preservation in patients with early AD
[7, 8]. In amyotrophic lateral sclerosis (ALS) and Parkinson’s
disease animal models, the TZD pioglitazone ameliorated
the disease symptoms [9, 10]. In rodent focal ischemia
models, both pioglitazone and rosiglitazone decreased the
infarct volume [11–13]. Furthermore, the natural agonist
15d-PGJ2 was shown to decrease the neurological deﬁcits
after experimental intracerebral hemorrhage [14] and its
plasmalevelsinstrokepatientswerefounddirectlycorrelated
to the neurological outcome [15]. Rosiglitazone and piogli-
tazone decreased secondary neuronal damage, astrogliosis,
microglial activation, myelin loss, and neuropathic pain2 PPAR Research
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Figure 1: Cellular targets of PPAR-γ agonists in neurodegenerative
diseases. PPAR-γ agonists can control neuroinﬂammation, neu-
rodegeneration, and demyelination by eﬀecting several cellular tar-
getsandbyseveraldirectandindirectmechanisms.PPAR-γagonists
can control glial activation, preventing a number of proinﬂam-
matory activities that can contribute to myelin/OL damage and
neurotoxicity PPAR-γ agonists may also aﬀect OLs and neurons,
by preventing release inﬂammatory mediators and/or promote the
synthesis of soluble factors or membrane-bound molecules that
control glial activation.
in animal models of spinal cord injury while improving
motor function recovery [16]. In experimental autoimmune
encephalomyelitis (EAE), a well known model for autoim-
mune demyelinating diseases, synthetic, and natural PPAR-γ
ligands—as well as some PPAR-α or δagonists—have been
reported to ameliorate clinical symptoms, to reduce expres-
sion of pro-inﬂammatory cytokines and chemokines, to
decrease brain inﬂammation, demyelination and glial activa-
tion,andtodelaytheonsetofdisease[17–25]. More recently,
promising results obtained in experimental models of ocular
diseases have evidenced that PPAR-γ could be targeted to
control inﬂammation and treat invalidating diseases such
as diabetic retinopathy and optic neuritis, a demyelinating
disease of the optic nerve frequently associated to multiple
sclerosis (MS) (see for review [26]). Nonetheless, in spite
of the amount of data on the therapeutic activities of PPAR
agonists in EAE, clinical studies are still lacking and reports
on their clinical use in MS or optic neuritis are still anecdotal
[27]. Clinical trials are, however, in course with pioglitazone
and rosiglitazone [5].
The beneﬁcial eﬀects of PPAR-γ agonists in degenerative,
inﬂammatory and traumatic brain pathologies are most
likely mediated by several mechanisms, which may be
disease-speciﬁc and involve both peripheral and central anti-
inﬂammatory activities, by aﬀecting crucial functions of
peripheral (macrophages and/or lymphocytes) and central
(microglial cells) immune cells. Besides microglia, PPAR-
γ agonists can act on other neural cell types, including
astrocytes, neurons, and oligodendrocytes (Figure 1).
Several of the beneﬁcial eﬀects of PPAR-γ result from
its ability, once activated by speciﬁc ligand, to control the
expression of proinﬂammatory genes, through the binding
of speciﬁc sequences in their promoter regions—the per-
oxisome proliferator response elements (PPREs)—but also
independently from its DNA-binding activity, by a mecha-
nism termed transrepression, which have just begun to be
elucidated [28]. In addition, some PPAR-γ ligands may exert
speciﬁc activities independently from PPAR-γ. Among these,
of great interest is the ability of a few TZDs to directly
inﬂuence mitochondrial function by binding to target sites
in mitochondria including the Complex I of the respiratory
chain and the newly described protein mitoneet [29].
2. PPAR-γ: STRUCTURE, FUNCTIONS, AND AGONISTS
The PPAR-γ and the two closely related PPAR-α and PPAR-δ
(also known as β, NUC-1, or FAAR) share a high homology,
but diﬀer for tissue distribution and ligand speciﬁcity [2].
PPAR-α is mainly expressed in tissues with high catabolic
rates of fatty acids, such as the liver, muscle, and heart,
whereasPPAR-δ showsamuchwiderdistribution.PPAR-γ is
highly expressed in adipose tissue and in cells of the immune
system, including lymphocytes and macrophages. In the
brain, PPAR-γ is expressed in several cell types including
microglia, astrocytes, oligodendrocytes, and neurons.
PPAR-γ protein shows a remarkable conservation across
species. Human and the murine PPAR-γ proteins show
95% identity at the amino acid level. The human PPAR-
γ gene is located on chromosome 3 and generates at least
three mRNA transcripts, PPAR-γ1, PPAR-γ2, and PPAR-
γ3[ 30–32]. PPAR-γ1 e PPAR-γ3 mRNAs encode for the
same protein, while PPAR-γ2m R N Ag i v e sr i s et oap r o t e i n
containing 28 additional amino acids at the N-terminus.
At protein level, all three PPARs show a similar organi-
zation in ﬁve diﬀerent functional domains, two of which—
the DNA-binding domain (DBD) and the ligand-binding
domain (LBD)—are the highly conserved [2]. The DBD
contains the two zinc ﬁnger-like motifs that recognize the
DNA target, and can be considered the hallmark of the nu-
clear receptor superfamily. The LBD conserves a common
three-dimensional structure, which hosts a particularly large
ligand-binding cavity, of which only 30–40% is occupied
by the ligand. The relatively free nonspeciﬁc interaction
between the cavity and the hydrophobic domains of the
ligandexplainsthelowligand-speciﬁcityofPPARs.Nonethe-
less, the LBDs of the three PPAR isotypes have suﬃciently
divergent amino acid sequences to allow some ligand speci-
ﬁcity.
SeveralunsaturatedfattyacidsbindtoallthreePPARiso-
forms,whereassaturatedfattyacidsareingeneralpoorPPAR
ligands. However, given the relatively high concentration of
lipids required for PPAR activation (in the micromolar or
submicromolar concentration range), their “in vivo” role as
PPAR ligands remains a controversial issue. Some arachi-
donic acid metabolites are more eﬀective PPAR-γ ligands
than the precursor. In particular, 15d-PGJ2,c h a r a c t e r i z e db y
areactiveα,β-unsaturatedketoneinthecyclopentenonering,
wastheﬁrstPPAR-γ endogenousligand,describedin1995by
two independent groups [33, 34].A. Bernardo and L. Minghetti 3
The implication of PPAR-γ in several important
metabolic and degenerative disorders, has strongly pushed
the research of speciﬁc PPAR-γ agonists and antagonist
(for review see [35]). A major group of synthetic PPAR-
γ agonists is represented by the antidiabetic drugs TZDs,
originally identiﬁed for their ability to improve the insulin
sensitivityofdiabeticanimals.Pioglitazoneandrosiglitazone
belong to this group of high-aﬃnity ligand. A diﬀerent
series of synthetic PPAR-γ ligands are derived by L-tyrosine
GI262570, GW1929, and GW7845, which were developed
on the basis of their activity on human PPAR-γ and are
among the most potent PPAR-γ agonists, being active at low
nanomolar concentrations.
In addition to these groups of ligands, several members
of the heterogeneous NSAID family have been described
as agonists for PPARs [35] and reference therein. In most
cases, the doses required for PPAR-γ agonist activity are
in the high micromolar range, thus largely exceeding those
required for in vivo inhibition of cyclooxygenases (COXs),
the main target of these drugs. Among NSAIDs, aspirin and
acetaminophen(orparacetamol)lackofagonisticactivityfor
anyofthePPARsubtypes,whereasindomethacin,ibuprofen,
and diclofenac are selective for the γsubtype. Recently,
we have shown that the two nitric oxide (NO)-releasing
derivative of ﬂurbiprofen, HCT1026 and NXC 2216, were
both able to activate PPAR-γ and induce its speciﬁc binding
to a PPRE sequence [36, 37]. Few antagonists are also
available, but their use is often limited by partial agonistic
activity.TheplasticizerbiphenolAdiglycidylether(BADGE)
and the irreversible antagonist GW9662 are among the most
widely used.
3. PPAR-γ AGONISTS AND
OLIGODENDROCYTE BIOLOGY
Oligodendrocytes (OLs) are the myelin-forming cells of the
CNS. Their diﬀerentiation from precursor to mature cells
occurs through a series of stages that can be deﬁned by
morphological and antigenic changes occurring in vivo as
well as in culture systems [38]. During development and
repair OLs extend elongated processes, forming multilamel-
lar sheaths around neuronal axons. The formation, growth,
and maintenance of the myelin sheath are prominent parts
of neural development and nervous system function. As for
OL maturation, myelin formation is a multistep process,
involving recruitment to germination sites, proliferation of
undiﬀerentiated OL progenitors and their diﬀerentiation
to mature OLs, producing myelin. Damage to OLs as a
result of oxidative stress is considered a key pathogenetic
pathway in several adult and infant human diseases. A
substantial number of in vitro and in vivo studies has shown
a maturation-dependent vulnerability to oxidative stress of
the OL lineage [39–41], suggesting that OL progenitor is a
keytargetforlimitwhitematterdamageandpromotemyelin
repair [42]. Oligodendrocytes are major lipid producing
cells, as required for myelin formation and maintenance.
Given the role of PPARs in lipid metabolism it is conceivable
that this group of nuclear receptor play a major role in OL
diﬀerentiation and function. Although PPAR-β/δ has been
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Figure 2: PPAR-γ expression in culture rat oligodendrocytes and
in white matter (postnatal day 19) in rat model of global perinatal
asphyxia. (a) Immunocytochemistry of rat OL progenitor cultures,
prepared as previously described [40]f o rP P A R - γ (upper panel)
and the OL marker O4 (lower panel). (b) Western blot analysis of
white matter homogenates from rats at postnatal day 19 subjected
to 20 minutes of perinatal asphyxia (hypoxic) and from controls,
prepared as described in Piscopo et al. [48]. Inset show the
decreased levels of MBP in hypoxic rats at pnd 19.
long considered the PPAR type mainly expressed in OLs and
involved in myelination [43, 44], recent ﬁndings support an
important role for PPAR-γ activators in OL protection and
diﬀerentiation. The ﬁrst evidence for a role of PPAR-γ in OL
diﬀerentiation was reported by Roth et al. [45]. By using the
B12, oligodendrocyte-like cell line and primary cultures of
spinal cord OL precursors, the authors ﬁrst demonstrated
that these cells expressed all three PPAR isoforms and found
that natural and synthetic PPAR-γ agonists, but not other
isoform activators, enhance process extension and cell matu-
ration. These eﬀects were blocked by the PPAR-γ antagonist
GW9662. The maturation of pre-OLs was accompanied by
enhanced expression of alkyl-dihydroxyacetone phosphate
synthase (ADAPS), a peroxisomal enzyme required for the
synthesis of plasmalogen, an etherphospholipid essential for
myelin formation. These observations suggest that PPAR-γ
mediated mechanisms may be important for OL diﬀerentia-
tion and peroxisome functions. An important role for these
organelles in maintaining OL and white matter integrity has
been recently demonstrated in mutant mice characterized
by the selective absence of functional peroxisomes from OLs
[46]. In line with the proposed role of PPAR-γ in controlling
OLdiﬀerentiationandfunctions,wehaverecentlyconﬁrmed
the expression of PPAR-γ in highly puriﬁed rat OL cultures
(Figure 2(a)). The level of expression is increased with the
OL maturation in vitro (Bernardo et al., in preparation). In
addition, we found an increased expression of PPAR-γ in
white matter of young rats (post natal day 19) exposed to
perinatal global asphyxia (Figure 2(b)). This model mimics
some of the features of perinatal asphyxia, a major cause
of immediate and delayed brain damage in the newborn
[47,48],andischaracterizedbyearlyoxidativestress,delayed
behavioral deﬁcits, and alteration in myelin formation, as
indicated by the strong reduction of myelin basic protein
(MBP) expression (Figure 2(b)). Whether PPAR-γ over-
expression is part of an adaptive response to the hypoxic4 PPAR Research
condition aimed at restoring myelin formation or is part of
an aberrant program leading behavioral impairment remain
to be established.
In apparent contrast with the above ﬁndings, Xiang
et al. [49], reported that the PPAR-γ natural ligand 15d-
PGJ2, but not other PGs, induced apoptosis of OL precursor
cell lines (mOP and CG4 cell lines). The toxic eﬀect was
developmental stage-dependent, being the undiﬀerentiated
mOP cells more susceptible than diﬀerentiated cells. In line
with observations previously reported in microglia cultures
[50], cell death was independent of the nuclear receptor
PPAR-γ. Since the toxic eﬀect of 15d-PGJ2 was prevented
by preincubation of cell cultures with N-acetyl cysteine, a
reducing agent and a precursor molecule for glutathione
(GSH) synthesis, but not with free radical scavengers, the
authors suggest that the underlying mechanism is related to
oxidative stress due to depletion of GSH.
4. PPAR-γ AGONISTS AND ASTROCYTES
Astrocytes are most abundant glial cells in the CNS and
crucialplayersin brainhomeostasis. Among otherfunctions,
they provide metabolic support for neurons, uptake neu-
rotransmitters such as glutamate, synthesize neurotrophic
factors, and contribute to ion homeostasis (i.e., potassium
uptake) and blood-brain barrier induction and maintenance
[51]. In addition, astrocytes exert important roles also in
brain inﬂammation and immunity, as they express several—
though fewer than microglia—pattern-recognition receptors
(PRRs) such as for example the Toll-like receptors, and
release cytokines and chemokines that can trigger or amplify
the local inﬂammatory response [52]. Similar to microglia,
astrocytes rapidly react to a wide array of insults or dam-
aging events. Reactive astrocytes, which are characterized by
increased expression of glial ﬁbrillary acidic protein (GFAP),
a constituent of the intermediate ﬁlaments, are typical
of most brain pathologies. Thus astrocytes represent an
important target for anti-inﬂammatory and neuroprotective
therapeutic strategies.
Astrocytes express PPAR-γ [53, 54], and accumulating
evidence over the last ten years indicates that PPAR-γ
agonists modulate astrocyte functions.
Inratcorticalslicesandculturedastrocytes,theTZDpio-
glitazone was found to signiﬁcantly increase glucose con-
sumption in time- and dose-dependent manners, through
a mechanism independent of PPAR-γ and involving cAMP/
PKA signaling [55]. Pioglitazone did not modify the expre-
ssion of the glucose transporter GLUT-1, which is mainly
expressed in glial and endothelial cells, but rather it
increased glucose ﬂux through pre-existing GLUT-1 protein.
In addition, pioglitazone increased lactate production and
release, induced mitochondrial membrane hyperpolariza-
tion, and protected astrocytes against hypoglycemia-induced
cell death. On the basis of their studies, the authors suggest
that TZDs modulate enzyme activities present within the
mitochondrial membrane causing increased cytosolic pyru-
vate, resulting in greater lactate production. The inhibitory
eﬀect on mitochondrial function is compensated by an
increase in anaerobic glycolysis allowing for continued ATP
production. Eventually, the reduced intracellular glucose
levels are replenished by glucose transport through the
GLUT-1. At later times, mitochondrial respiration recovers,
and accumulated ATP utilized to maintain and increase
the membrane potential. Because hyperpolarization of the
mitochondrial membrane is postulated to be protective,
the net result of TZD treatment, at least in astrocytes, is
protective and allows cells to withstand subsequent noxious
stimuli [55]. Altogether, these results suggest that TZD-
induced alteration of astrocyte metabolism and mitochon-
drial function could be beneﬁcial in neurological conditions,
in which glucose availability is reduced.
Another important mechanism by which PPAR-γ ago-
nists could exert neuroprotection by inﬂuencing astrocyte
functions is the enhancement of glutamate uptake. Romera
et al. [56] reported that the PPAR-γ antagonists T0070907
prevented the ischemic preconditioning-induced (IPC) neu-
roprotection in neuronal-astrocytic cocultures subjected
to oxygen-glucose deprivation (ODG) and reversed the
inhibitory eﬀect of IPC on OGD-induced glutamate release.
In addition, rosiglitazone and the non-TZD agonist L-
796,449 induced a concentration-dependent increase in
glutamate transporter GLT-1 expression and [3H] glutamate
uptake in rat astrocytes. In addition the authors identiﬁed
six putative PPREs in the promoter region of GLT1/EAAT2
gene, suggesting GLT1/EAAT2 glutamate transporter is a
novel PPAR-γ target gene [56]. Finally, 15d-PGJ2 remarkably
increase the synthesis and release of neurotrophic factor
nerve growth factor (NGF) in mouse primary astrocytes,
which could further contribute to neuroprotection [57].
As mentioned above, activated astrocytes produce cytok-
ines and other molecules involved in inﬂammatoryresponse,
which are thought to signiﬁcantly contribute to brain da-
mage. Such neurotoxic activities have been shown to
be reduced by PPAR-γ agonists in several experimen-
tal paradigms. The two TZD compounds NP00111 and
NP01138 were reported to inhibit the production of nitric
oxide (NO), IL-6, and TNF-α as well as expression of
the inducible enzymes iNOS and COX2 induced in LPS-
stimulated astrocyte and microglial cultures [58]. Con-
sistently with the described anti-inﬂammatory activities,
the two compounds were neuroprotective in an animal
model in which of brain damage is induced by kainic acid
administration [59]. Both in vitro and in vivo eﬀects were
substantially attenuated by cotreatment with the PPAR-γ
antagonist GW9662, supporting the involvement of PPAR-γ
activation.
In contrast to the above described TZDs, the natu-
ral ligand 15d-PGJ2 prevented the IL-1β-induced COX-
2 mRNA accumulation in human astrocytes, through a
PPARγ-independent mechanism [60]. Similarly, Lennon
and colleagues [61] showed that ciglitazone and 15d-PGJ2
activated the MAP kinase cascades (Erk, Jnk, and p38 MAP
kinase) in astrocytes by a PPAR-γ independent mechanism,
whichrequiredthepresenceofROS.Again,independentlyof
PPAR-γ, 15d-PGJ2 and rosiglitazone reduced the phospho-
rylation of signal transducers and activators of transcription
(STAT) 1 and 3 as well as Janus kinase 1 (JAK1) and JAK2 in
activated astrocytes and microglia [62].A. Bernardo and L. Minghetti 5
Recently, Xu and Drew [63] extended the analysis of
the anti-inﬂammatory activity of PPAR-ligands to other
inﬂammatory mediators belonging to the IL-12 family of
cytokines. They found that in primary astrocytes, LPS
induced the production of IL-12p40, IL-23, and IL-27p28
proteins, which was signiﬁcantly reduced in the presence
of 15d-PGJ2. Since these cytokines play critical roles in the
diﬀerentiation of T helper (Th) 1 and Th17 cells and are
likely to contribute to the development of multiple sclerosis,
this observation furthersupport the potential role of PPAR-γ
agonists in MS treatment [5, 64].
In line with the beneﬁcial eﬀect of PPAR-γ agonists in
experimental models of inﬂammatory diseases, PPAR-γ has
also been involved in anti-inﬂammatory functions of IL-4,
a Th2 type cytokine, which plays an important role in con-
trolling Th1 cell responses and resolution of inﬂammation.
Paintlia et al. [65] demonstrated that the inhibition of iNOS
expression and the increase of survival of diﬀerentiating OPs
induced by IL-4 in inﬂammatory cytokine-stimulated mixed
cultures are mediated by PPAR-γ activation. In support of
their conclusions, the authors describe a coordinate increase
in the expression of both PPAR-γand its natural ligand-
producing enzyme 12/15-lipoxygenase (12/15-LOX) in IL-
4-treated glial cells and show that IL-4-induced PPAR-γ
activation antagonizes NF-κB transactivation in inﬂamma-
tory cytokine-stimulated astrocytes. A similar upregulation
of PPAR-γ by IL-4 was demonstrated in cultured microglial
cells [66]. To link between IL-4 and PPAR-γ is completed
by the observation that the anti-inﬂammatory activity of the
TZD troglitazone was mediated by its ability to increase IL-4
expression in glial cultures [67].
Astrocytes recognize and react to several pathogens
through their repertoire of PPRs [52]. In a recent study,
15d-PGJ2 and ciglitazone suppress the production of IL-1β
andNOinStaphylococcusaureus-stimulatedastrocytes[68].
Interestingly,15d-PGJ2 attenuatedTLR2expression,thePPR
recognizing Staphylococcus aureus. Importantly, 15d-PGJ2
and ciglitazone were still capable of inhibiting the release
of proinﬂammatory mediators induced by Staphylococcus
aureus in PPAR-γ-deﬁcient astrocytes, supporting PPAR-
γ-independent eﬀects of these compounds. In another
study, 15d-PGJ2 signiﬁcantly attenuated astrocyte reaction
to mycotoxin ochratoxin A (OTA), a widespread food
contaminant that accumulates in the brain. At noncytotoxic
concentrations,OTAdown-regulatedGFAPexpressionwhile
it upregulated vimentin. Interestingly, OTA increased PPAR-
γ expression, possibly increasing the susceptibility of OTA-
exposed cells to PPAR-γ agonist treatment [69].
5. PPAR-γ AGONISTS AND MICROGLIAL CELLS
Microglia derive from myeloid precursors that enter the
developing CNS to become the major population of
brain resident macrophages. Under physiological conditions,
microglia show a ramiﬁed morphology and the absence of
cell-surface and cytoplasmic molecules typically associated
with other tissue macrophages. In this quiescent or “resting”
state microglia are able to “sense” subtle environmental
changes to which they rapidly react [70]. Although our
knowledge on microglial in physiological conditions is still
limited, using transgenic mice showing speciﬁc expression
of enhanced green ﬂuorescent protein in microglia and in
vivo two-photon microscopy, it was shown that “resting”
microglia constantly survey the surrounding microenviron-
ment with extremely motile processes and protrusions [71].
Once activated, microglia rapidly undergo morphological
changes, characterized by cell body enlargement, loss of
ramiﬁed processes, and upregulation of cell-surface and/or
cytoplasmic antigens. In addition, activated microglia can
synthesize a range of diﬀerent molecules, including free
radicals, inﬂammatory cytokines, chemokines, lipid medi-
ators, and neurotrophic factors, whose typical proﬁle will
determine the outcome of microglial activation in term
of repair or injury [70]. Although in the past activated
microglia have been regarded mainly as detrimental for the
surrounding cells and as major players in neurodegenerative
processes, it is now clear that activated microglia play
complex and multifaceted roles, which need to be deﬁned
within each disease. Importantly, the diﬀerent states of
activation can be switched between one state and another
during the course of disease or in response to further stimuli
or signals from the periphery [72].
A deeper knowledge of microglial biology and of the
molecular mechanisms underlying the acquisition of protec-
tive versus detrimental functions is crucial for ﬁnding new
molecular targets and developing eﬀective treatments for a
wide range of neurological disorders.
In this view, PPAR-γ agonists have been extensively
studied in the last decade for their therapeutic potential as
key molecules in preventing the undesired toxic eﬀects of
microglial activation [35, 73].
One of the ﬁrst ﬁnding supporting a role for 15d-
PGJ2 asendogenousregulatorofmicroglialactivation—15d-
PGJ2 derives from PGD2, a major PG synthesized within
the brain by most neural cells—was provided by Petrova
et al. [74], who demonstrated that this PPAR-γ natural
ligand attenuates iNOS expression, and the subsequent
NO accumulation, in the murine BV-2 microglial cell line
stimulated by LPS. Since the TZD troglitazone did not aﬀect
the NO pathway, it was suggested that 15d-PGJ2 inhibits
iNOS expression by a PPAR-γ independent mechanism. The
sameauthorsthendemonstratedthat15d-PGJ2 decreasesthe
production of TNF-α,I L - 1 β and the expression of COX-2 in
the same cell system while increasing the expression of the
antioxidant enzyme hemeoxygenase-1 and the intracellular
levels of glutathione [75].
Bernardo et al. [76] showed for the ﬁrst time that pri-
mary microglial cells, unlike BV-2 cells, express PPAR-γ
and that such basal expression is increased by its speciﬁc
agonists, while it is reduced in the presence of microglial
activators such as LPS and IFN-γ. Microglial PPAR-γ was
subsequently shown to be functionally active, being able to
bind speciﬁc PPRE sequences upon activation by natural
and synthetic agonists [50] .S i m i l a rt oB V - 2c e l ll i n e ,
in primary microglial cultures 15d-PGJ2 prevented LPS-
induced iNOS expression and TNF-α production as well
as IFN-γ-induced expression of major histocompatibility
complex (MHC) class II antigens, by mechanisms involving6 PPAR Research
PPAR-γ activationandreducedactivationofSTAT-1andNF-
κB, which are known to mediate IFN-γ and LPS signaling
[76]. In human microglial cells, 15d-PGJ2 did not aﬀect NF-
κB binding activity although it decreased STAT-1 expression
and enhanced expression and binding activity of the AP-
1 proteins J-Jun and c-Fos [60]. It was then reported that
15d-PGJ2 inhibits IL-12 synthesis in rat primary microglia
and mouse cell line N9, activated either by LPS alone or
in combination with IFN-γ or TNF-α [63, 77]. 15d-PGJ2
attenuated microglial activation also when elicited by Gram-
positive bacteria Staphylococcus aureus, by inhibiting the
expressionofproinﬂammatorycytokinesandthechemokine
monocyte chemoattractant protein-1 (MCP-1) [73, 78].
In cortical mixed neuron-glial cultures 15d-PGJ2, cigli-
tazone and troglitazone prevented LPS-induced neuronal
death, suggesting a PPAR-γ mediated mechanism of neu-
roprotection [79]. Similarly, 15d-PGJ2, ciglitazone, troglita-
zone and two NSAIDs indomethacin and ibuprofen reduced
the neurotoxicity of microglial cells exposed to β-amyloid
ﬁbrils [80]. In this cell system, COX-2-speciﬁc inhibitors
failed to promote neuronal survival, suggesting protective
mechanisms independent of COX-2 metabolism.
In addition to indomethacin and ibuprofen, we have
reported that two NO-releasing derivative of ﬂurbiprofen,
HCT1026 and NXC 2216, were able to prevent microglial
activation by activating PPAR-γ [36, 37]. Interestingly, NCX
2216 after an initial activation induced PPAR-γ nitration
and inactivation. These eﬀects were paralleled by a transient
reduction of TNF-α and NO production and a protracted
inhibitionofIL-1βandPGE2 synthesis,suggestingadynamic
regulation of the functional state of activated microglia by
NCX 2216. Long treatment with NCX 2216 could therefore
lead, after an initial activation of PPAR-γ,t oap r o t r a c t e d
suppression of its control over microglial activation. Our
results could help explaining why among the few NSAIDs
withAβ-loweringactivity(reviewedby[81]),onlyinthecase
of protracted administration of NCX 2216 in an AD animal
model, the reduction of cerebral amyloid load accompanied
by a sustained microglial activation [82].
The contribution of PPAR-γ-dependent or independent
mechanisms to the inhibition of microglial activation by
15d-PGJ2 seems dependent on the cell type (primary versus
transformed cell lines; fetal versus neonatal), or on concen-
tration of the ligand. In rat primary microglial cultures, we
haveshown[50]that15d-PGJ2 atconcentrationsseveralfold
lower than those required for PPAR-γ activation, eﬀectively
reduced the LPS-stimulated production of PGE2 by directly
preventing the enzymatic activity of COX-2 rather than its
expression, as previously described in activated monocytic
cell lines [80, 83] and in BV-2 cells [75]. The reduction of
COX-2 enzymatic activity could be achieved through the
modiﬁcations of key cysteine residues [84], as suggested by
the ability of 15d-PGJ2 electrophilic α,β-unsaturated ketones
to modify several cellular proteins [85, 86]. At concentration
10 times higher than those required to activate PPAR-γ, 15d-
PGJ2 induced microglial cell impairment and death by apop-
tosis [50]. The eﬀects were stronger in activated microglia
than in unstimulated cells, suggesting that this agent may
prevent excessive microglial activation by promoting their
elimination by apoptosis thus contributing to the resolution
of inﬂammation as previously suggested in peripheral tissues
[87, 88].
Although apoptosis by 15d-PGJ2 has been shown in sev-
eral cells, the link between the proapoptotic eﬀect of 15d-
PGJ2 and PPAR-γ activation is still controversial. As before
this may be linked to cell types and their degree of diﬀer-
entiation or transformation. For example, as opposed to the
observations reported in primary microglia, the induction
of apoptosis in T-cells and human and rat glioma cell lines
appears mediated by PPAR-γ-dependent mechanisms [61,
87, 89–91].
6. CONCLUSIONS
In the last decade, there has been an increasing number of
experimental studies supporting the use of PPAR-γ ligands
to treat major disabling brain diseases, with a high social
burden and impact on health case system. The compelling
evidence obtained in experimental studies is complemented
by sparse, but very encouraging clinical studies. The positive
outcomes in animal models of AD, due to the ability of
PPAR-γ agonists to reduced inﬂammation and the amyloid
burden by various mechanisms, have found some validation
in a pilot clinical trial in which AD patients treated for
6 months with rosiglitazone showed reduced attention
and memory deﬁcits [7]. In a second recent trial, the
improvement in cognition after 6 months of rosiglitazone
treatment was signiﬁcant only in AD patients who did not
have the ε4 allele of the apolipoprotein E [92] ,ag e n o t y p e
associate with a higher risk to develop AD. Similarly, the
better neurological outcome reported after administration of
PPAR-γ ligands in experimental stroke models are consistent
with the result of a small clinical trial reporting that patients
with diabetes receiving pioglitazone or rosiglitazone had
an improved functional recovery after stroke compare to
patients, who have not used any TZD [93]. Furthermore,
a large clinical trial has demonstrated that pioglitazone
reduced the combined risk of heart attack, stroke, and death
in high risk type 2 diabetes patients [94].
The clinical use of PPAR-γ agonists in MS and ASL re-
mains poorly investigated. Nonetheless, in a case report,
pioglitazonetreatmentofanMSpatientresultedinincreased
body weight and improved motor strength and coordination
[27]. A ﬁrst clinical trial for the use of pioglitazone in ALS
started in Germany in late 2007.
Although PPAR-γ synthetic ligands such as TZDs and
NSAIDs appear to be very promising drugs to treat severe
human diseases, from cancer to metabolic diseases to brain
diseases, several open issues still need to be examined.
Among these, the toxic eﬀect associated with some PPAR-γ
agonists and their blood-brain-barrier permeability, which
are at present still matter of controversies. A deep knowledge
of the molecular mechanisms evoked by PPAR-γ ligands
either dependent or independent of the receptor activation
and of the dependence of such eﬀects on the speciﬁc cell
typeismandatoryforthedevelopmentofPPAR-γ drugswith
increasing eﬃcacy and safety.A. Bernardo and L. Minghetti 7
ABBREVIATIONS
15d-PJ2: 15-deoxy-Δ12,14-prostaglandin J2
AD: Alzheimer disease
ALS: Amyotrophic lateral sclerosis
AP-1: Activator protein-1
CNS: Central nervous system
COX: Cyclooxygenase
DBD: DNA-binding domain
EAE: Experimental autoimmune
encephalomyelitis
HODE: Hydroxy octadecadienoic acids
IFN: Interferon
IL: Interleukin
iNOS: Inducible nitric oxide synthase
JAK: Janus activated kinases
LBD: Ligand-binding domain
LPS: Lipopolysaccharide
MAPK: Mitogen-activated protein kinase
MCP-1: Monocyte chemoattractrant protein-1
MHC: Major histocompatibility complex
MS: Multiple sclerosis
NFκB: Nuclear factor κB
NO: Nitric oxide
NSAIDs: Nonsteroidal anti-inﬂammatory drugs
oxLDL: Oxidized low-density lipoprotein
PD: Parkinson disease
PPAR: Peroxisome proliferator-activated receptor
PPRE: Peroxisome proliferator response Elements
RXR: Retinoid X-receptor
SOCS: Suppressor of cytokine signalling
STAT: Signal transducer and activators of
transcription
Th: T helper cell
TNF: Tumour necrosis factor
TZDs: Thiazolidinediones
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